Top

Cancer Chemotherapy and Pharmacology

Published in:

01-07-2008 | Original Article

Irinotecan plus cisplatin and dexamethasone (ICD) combination chemotherapy for patients with diffuse large B-cell lymphoma previously treated with Rituximab plus CHOP

Authors: Hye Jin Kang, Won Seog Kim, Cheolwon Suh, Yeon Hee Park, Bong Seog Kim, Young Jin Yuh, Baek-Yeol Ryoo

Published in: Cancer Chemotherapy and Pharmacology | Issue 2/2008

Abstract

Purpose

The therapeutic strategy for relapsed or refractory patients with diffuse large B-cell lymphoma (DLBL) remains challenging yet. Salvage therapy has been tried for these patients according to their clinical status. We studied ICD (irinotecan, cisplatin and dexamethasone) regimen as salvage chemotherapy for DLBL patients previously treated with RCHOP.

Methods

Between February 2005 and May 2006, 15 patients were treated prospectively with ICD chemotherapy; irinotecan 65 mg/m²/day on days 1 and 8, cisplatin 30 mg/m²/day on days 1 and 8, and dexamethasone 40 mg/day on days 1–2 and 8–9. This schedule was planned to repeat every 3 weeks until disease progression, severe toxicity or stem cell transplantation.

Results

Of the 14 patients evaluable for response, 3 patients achieved CR, 7 patients PR, with 1 SD and 3 PD; overall response rate 71% (10/14; 95% confidence interval, 47–95%). The median progression free survival (PFS) and event free survival (EFS) were 113 (range 21–493+) and 77 (range 21–324+) days, respectively. The median overall survival was 267 (range 31–493+) days. Grade 3/4 neutropenia and grade 3 neutropenic fever were observed in 67% (22/33) and 18% (6/33) of cycles, respectively. There were 20% of grade 3/4 nausea and diarrhea observed.

Conclusions

The ICD regimen with current schedule showed high response rate for DLBL patients previously treated with RCHOP. But the high incidence of neutropenia led to delay of subsequent cycles causing dose intensity reduced, which seems to be related with short PFS and EFS.

Armitage JO, Weisenburger DD (1998) New approach to classifying non-Hodgkin’s lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin’s Lymphoma Classification Project. J Clin Oncol 16:2780–2795PubMed

Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235–242PubMedCrossRef

Pfreundschuh M, Trumper L, Osterborg A, Pettengell R, Trneny M, Imrie K, Ma D, Gill D, Walewski J, Zinzani PL, Stahel R, Kvaloy S, Shpilberg O, Jaeger U, Hansen M, Lehtinen T, Lopez-Guillermo A, Corrado C, Scheliga A, Milpied N, Mendila M, Rashford M, Kuhnt E, Loeffler M; MabThera International Trial Group (2006) CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7:379–391PubMedCrossRef

Kantarjian H, Barlogie B, Plunkett W, Velasquez W, McLaughlin P, Riggs S, Cabanillas F (1983) High-dose cytosine arabinoside in non-Hodgkin’s lymphoma. J Clin Oncol 1:689–694PubMed

Adelstein DJ, Lazarus HM, Hines JD, Herzig RH (1985) High-dose cytosine arabinoside in previously treated patients with poor-prognosis non-Hodgkin’s lymphoma. Cancer 56:1493–1496PubMedCrossRef

Velasquez WS, Cabanillas F, Salvador P, McLaughlin P, Fridrik M, Tucker S, Jagannath S, Hagemeister FB, Redman JR, Swan F. Barlogie B (1998) Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood 71:117–122

Press OW, Livingston R, Mortimer J, Collins C, Appelbaum F (1991) Treatment of relapsed non-Hodgkin’s lymphomas with dexamethasone, high-dose cytarabine, and cisplatin before marrow transplantation. J Clin Oncol 9:423–431PubMed

Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, Sonneveld P, Gisselbrecht C, Cahn JY, Harousseau JL (1995) Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med 333:1540–1545PubMedCrossRef

Tobinai K, Hotta T, Saito H, Ohnishi K, Ohno R, Ogura M, Ariyoshi Y, Takeyama K, Kobayashi T, Ohashi Y, Shirakawa S (1996) Combination phase I/II study of irinotecan hydrochloride (CPT-11) and carboplatin in relapsed or refractory non-Hodgkin’s lymphoma. Jpn J Clin Oncol 26:455–460PubMed

10.

Tsuda H, Takatsuki K, Ohno R, Masaoka T, Okada K, Shirakawa S, Ohashi Y, Ota K (1994) Treatment of adult T-cell lymphoma with irinotecan hydrochloride (CPT-11). Br J Cancer 70:771–774PubMed

11.

Niitsu N, Iijima K, Chizuka A (2001) Combination therapy with irinotecan (CPT-11), mitoxantrone, and dexamethasone in relapsed or refractory non-Hodgkin’s lymphoma: a pilot study. Ann Hematol 80:411–416PubMedCrossRef

12.

Sugiyama K, Omachi K, Fujiwara K, Saotome T, Mizunuma N, Takahashi S, Ito Y, Aiba K, Horikoshi N (2002) Irinotecan hydrochloride for the treatment of recurrent and refractory non-Hodgkin’s lymphoma. Cancer 94:594–600PubMedCrossRef

13.

Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-Lopez A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP (1999) Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17:1244–1253PubMed

14.

Ota K, Ohno R, Shirakawa S, Masaoka T, Okada K, Ohashi Y, Taguchi T (1994) Late phase II clinical study of irinotecan hydrochloride (CPT-11) in the treatment of malignant lymphoma and acute leukemia. Gan To Kagaku Ryoho 21:1047–1055PubMed

15.

Ribrag V, Koscielny S, Vantelon JM, Ferme C, Rideller K, Carde P, Bourhis JH, Munck JN (2003) Phase II trial of irinotecan (CPT-11) in relapsed or refractory non-Hodgkin’s lymphomas. Leuk Lymphoma 44:1529–1533PubMedCrossRef

16.

Sarris AH, Phan A, Goy A, Romaguera J, Hagemeister FB, Rodriguez MA, McLaughlin P, Pro B, Medeiros LJ, Samuels B, Mesina O, Bleyer AW, Cabanillas F (2002) Irinotecan in relapsed or refractory non-Hodgkin’s lymphomas. Indications of activity in a phase II trial. Oncology (Williston Park) 16(Suppl 7):27–31

17.

Saotome T, Takagi T, Sakai C, Kumagai K, Tamaru J (2000) Combination chemotherapy with irinotecan and adriamycin for refractory and relapsed non-Hodgkin’s lymphoma. Ann Oncol 11:115–116PubMedCrossRef

18.

Hanna N, Bunn PA, Langer C, Einhorn L, Guthrie T, Beck T, Ansari R, Ellis P, Byrne M, Morrison M, Hariharan S, Wang B, Sandler A (2006) Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 24:2038–2043PubMedCrossRef

19.

Takagi T, Saotome T (2001) Chemotherapy with irinotecan (CPT-11), a topoisomerase-I inhibitor, for refractory and relapsed non-Hodgkin’s lymphoma. Leuk Lymphoma 42:577–586PubMedCrossRef

Title: Irinotecan plus cisplatin and dexamethasone (ICD) combination chemotherapy for patients with diffuse large B-cell lymphoma previously treated with Rituximab plus CHOP
Authors: Hye Jin Kang
Won Seog Kim
Cheolwon Suh
Yeon Hee Park
Bong Seog Kim
Young Jin Yuh
Baek-Yeol Ryoo
Publication date: 01-07-2008
Publisher: Springer-Verlag
Published in: Cancer Chemotherapy and Pharmacology / Issue 2/2008
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-007-0607-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2008

The relative bioavailability of gefitinib administered by granular formulation

Phase II study of rubitecan in recurrent or metastatic head and neck cancer

A phase I study of docetaxel with ketoconazole modulation in patients with advanced cancers

Mechanisms of enhanced tumoricidal efficacy of multiple small dosages of ranpirnase, the novel cytotoxic ribonuclease, on lung cancer

The depletion of cellular ATP by AG2034 mediates cell death or cytostasis in a hypoxanthine-dependent manner in human prostate cancer cells

Randomized phase II study of cisplatin and 5-FU continuous infusion (PF) versus cisplatin, UFT and vinorelbine (UFTVP) as induction chemotherapy in locally advanced squamous cell head and neck cancer (LA-SCHNC)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer